GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Additional Paid-In Capital

Formycon AG (XTER:FYB) Additional Paid-In Capital : €412.87 Mil(As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Additional Paid-In Capital?


Formycon AG's quarterly additional paid-in capital increased from Dec. 2022 (€343.42 Mil) to Jun. 2023 (€411.54 Mil) and increased from Jun. 2023 (€411.54 Mil) to Dec. 2023 (€412.87 Mil).

Formycon AG's annual additional paid-in capital increased from Dec. 2021 (€78.44 Mil) to Dec. 2022 (€343.42 Mil) and increased from Dec. 2022 (€343.42 Mil) to Dec. 2023 (€412.87 Mil).

Formycon AG Additional Paid-In Capital Historical Data

The historical data trend for Formycon AG's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Additional Paid-In Capital Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.24 76.99 78.44 343.42 412.87

Formycon AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.44 341.54 343.42 411.54 412.87

Formycon AG Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Formycon AG Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Formycon AG's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG (XTER:FYB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:MOR XTER:BIO XTER:HPHA XTER:BNN XTER:MDG1 XTER:T5O OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB
Traded in Other Exchanges
FYB:Germany FYB:Germany FYB:Germany
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Website
https://www.formycon.com
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines